SMS Pharmaceuticals stock score and checklist

SMS Pharmaceuticals (SMSPHARMA) ranked on quality, valuation and momentum against 1,356 NSE stocks, with an 18-point checklist. Prices as of 18 Nov 2026; results to the quarter ended Sep 2026.

· data for the trading session of Wed 18 Nov 2026

Quality
49 / 100
Average
From 6 of 6 components
Valuation
41 / 100
Fair
From 3 of 4 components
Momentum
84 / 100
Strong
From 4 of 5 components

Average quality · Fair · Strong momentum. Passes 11 of 16 applicable checks.

How each score is made

Every number is ranked against the same number for the other 1,355 scored stocks. The percentile is the share of them it beats (0–100); a score is the average percentile of the components the stock has.

Quality: 49 (Average)

Profitability, balance sheet strength and steady growth.

ComponentSMS PharmaceuticalsPercentile
Return on equity (ROE)Profit over the last four quarters ÷ average shareholders’ equity. Higher ranks higher.14.9%60
Return on capital employed (ROCE)Pre-tax profit + interest ÷ equity + borrowings. Higher ranks higher.14.3%45
Debt / equityBorrowings ÷ equity (lease liabilities are not in NSE filings, so not counted). Lower ranks higher.0.4130
Interest coverPre-tax profit + interest ÷ interest, last four quarters. Higher ranks higher.7.1×48
Profit growth consistencyShare of the last 8 quarters with profit above the same quarter a year earlier.8 of 8 quarters93
Free cash flow margin FY26Operating cash flow − capex, as a % of the year’s sales. Higher ranks higher.-8.0%17

Valuation: 41 (Fair)

What you pay for the business, compared with similar companies and with its own past. Lower multiples rank higher.

ComponentSMS PharmaceuticalsPercentile
P/E vs sector medianPrice ÷ last four quarters’ EPS, against the median of Pharma & healthcare. Cheaper ranks higher.37.7 ÷ 41.6 = 0.91×57
P/E vs own 5-year medianMedian P/E at the last five fiscal year ends (kept for F&O stocks). Cheaper ranks higher.no 5-year price historyn/a
P/B vs sector medianPrice ÷ book value per share, against the sector median. Cheaper ranks higher.5.30 ÷ 4.44 = 1.19×41
Free cash flow yield FY26Free cash flow ÷ market value. Higher ranks higher.-1.6%24

Momentum: 84 (Strong)

How the share price has been trending, against other stocks and NIFTY 50.

ComponentSMS PharmaceuticalsPercentile
RS rating12-month return with the latest quarter counted twice, ranked against all NSE stocks we track.95 / 9995
vs 200-day averageHow far the price is above (+) or below (−) its 200-day average.+18.8%83
vs 50-day averageHow far the price is above (+) or below (−) its 50-day average.+3.0%72
Place in 52-week range0% = at the 52-week low, 100% = at the 52-week high.78% of the way up85
6-month strength vs NIFTY 50Six-month return minus NIFTY 50’s six-month return.–n/a

18-point checklist

Simple yes/no tests on growth, returns, debt, valuation, trend, holdings and trading. A check is n/a when it doesn’t apply or the data isn’t there; it then doesn’t count either way.

Passes 11 of 16 applicable checks (2 n/a)
#CheckSMS PharmaceuticalsResult
1Profit up on a year ago (latest quarter)Rising profit is the main thing that lifts a share’s value over time.+57%Pass
2Sales up on a year ago (latest quarter)Profit growth lasts longer when it comes with more business, not just cost cuts.+30%Pass
3Profit up year on year in at least 6 of the last 8 quartersSteady growth is easier to rely on than one good quarter.8 of 8Pass
4Return on equity (ROE) of 15% or moreHow much profit the company earns on shareholders’ money.14.9%Fail
5Return on capital employed (ROCE) of 15% or moreProfit on all the capital in the business, borrowed money included.14.3%Fail
6Debt below half of equity (D/E under 0.5)Low debt leaves room to get through a bad year.0.41Pass
7Interest cover of 3× or moreOperating profit should cover interest costs comfortably.7.1×Pass
8Positive free cash flow (latest full year)Cash left after investment is what pays dividends and debt.−₹71 Cr (FY26)Fail
9P/E below its sector medianA lower P/E than similar companies means you pay less for each rupee of profit.37.7 vs 41.6Pass
10P/E below its own 5-year medianCompares today’s price tag with what the market usually paid for this stock.no 5-year historyn/a
11Price above its 200-day averageThe long-term trend: above the line means the price has been rising over the past ten months.+18.8%Pass
12Price above its 50-day averageThe medium-term trend over about ten weeks.+3.0%Pass
13RS rating of 70 or moreOutperformed at least 70% of NSE stocks over the past year.95Pass
14Promoter holding not reduced last quarterOwners cutting their stake can be a sign they see less value ahead.+0.00 pts to 68.1%Pass
15FII + mutual fund holding up last quarterLarge investors adding shares is a sign of institutional interest.-2.28 pts to 1.2%Fail
16Delivery % (60 days) above the market medianMore shares taken into demat accounts means more investors, fewer day traders.42% vs 48%Fail
17Not under ASM / GSM surveillanceNSE puts stocks with unusual price or volume moves under extra margin and trading rules.not listedPass
18Not in the F&O ban listIn a ban, open interest is near the market-wide limit and only position-reducing trades are allowed.not an F&O stockn/a

SMS Pharmaceuticals vs the Pharma & healthcare sector

Against the 116 scored stocks in Pharma & healthcare. All Pharma & healthcare stocks →

Scores vs sector median

ScoreSMS PharmaceuticalsSector median
Quality4954
Valuation4146
Momentum8466

Top 5 in Pharma & healthcare by quality score

StockQualityValuationMomentumChecks
GLAXO96395914/16
SANOFICONR96492312/16
Procter & Gamble Health92555212/15
Thyrocare Technologies89375511/16
CAPLIPOINT86653511/16

Questions

What is SMS Pharmaceuticals’s quality score?
SMS Pharmaceuticals’s quality score is 49 out of 100 (Average) on 18 Nov 2026, from 6 of 6 components: Return on equity (ROE) 14.9% (percentile 60); Return on capital employed (ROCE) 14.3% (percentile 45); Debt / equity 0.41 (percentile 30); Interest cover 7.1× (percentile 48); Profit growth consistency 8 of 8 quarters (percentile 93); Free cash flow margin FY26 -8.0% (percentile 17). It is a rank against 1,356 scored NSE stocks, not an absolute grade.
Is SMS Pharmaceuticals expensive?
On ChartMine’s relative valuation score SMS Pharmaceuticals scores 41 out of 100 (Fair) on 18 Nov 2026: its P/E of 37.7 is 0.91× the Pharma & healthcare median of 41.6; its P/B of 5.30 is 1.19× the sector median of 4.44; its free cash flow yield is -1.6%. The score compares these multiples with other NSE stocks; it says nothing about where the price will go.
How many checklist points does SMS Pharmaceuticals pass?
SMS Pharmaceuticals passes 11 of 16 applicable checks on 18 Nov 2026 (2 do not apply or lack data). Passed: profit up on a year ago (latest quarter), sales up on a year ago (latest quarter), profit up year on year in at least 6 of the last 8 quarters, debt below half of equity (D/E under 0.5), interest cover of 3× or more, P/E below its sector median and more. Failed: return on equity (ROE) of 15% or more, return on capital employed (ROCE) of 15% or more, positive free cash flow (latest full year), FII + mutual fund holding up last quarter, delivery % (60 days) above the market median.
How are these scores calculated?
Each score is the average percentile rank of its components among all scored NSE stocks. Quality uses ROE, ROCE, debt/equity, interest cover, how many of the last 8 quarters grew profit year on year, and free cash flow margin (banks, NBFCs and insurers: ROE and profit consistency). Valuation uses P/E against the sector median and against the stock’s own 5-year median, P/B against the sector, and free cash flow yield, with cheaper ranking higher. Momentum uses the RS rating, distance from the 200-day and 50-day averages, place in the 52-week range and 6-month return against NIFTY 50. Scores are relative and change every trading day.

For information and education only; this is not investment advice. ChartMine is not a SEBI-registered investment adviser or research analyst. Scores are relative ranks among NSE stocks and change daily as prices and filings change. Data: NSE daily price files, company results, balance sheets and shareholding filings; a few filings arrive late or contain errors.

See it live on your chart.ChartMine for TradingView.